Skip to main content

Advertisement

Log in

In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: A technical note

  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Conclusions

In vivo ocular availability of ketorolac was evaluated following ocular instillation of aqueous, oil, and ointment formulations to normal corneas of rabbits and monitoring ketorolac concentration in aqueous humor by HPLC. Compared with aqueous drop, sesame and soybean oil drops of ketorolac provided higher ocular availability followed by ophthalmic ointment. The ointment formulation provided maximum sustained effect. Ketorolac aqueous drop with BAC and EDTA improved the rate of ocular absorption though not the extent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Herch PS, Rice BA, Baer JC, et al. Topical nonsteroidal agents and corneal wound healing.Arch Ophthalmol. 1990;108:577.

    Google Scholar 

  2. Cooper CA, Bergamini MVW, Leopold IH. Use of flurbiprofen to inhibit corneal neovascularization.Arch Ophthalmol. 1980; 98:1102–1105.

    CAS  Google Scholar 

  3. Kraff MC, Sanders DR, Mcguigan L, Rannan MG. Inhibition of blood-aqueous humor barrier breakdown with diclofenac: a fluorometric study.Arch Ophthalmol. 1990;108:380–383.

    CAS  Google Scholar 

  4. Searle AE, Pearce JL, Shaw DE. Topical use of indomethacin on the day of cataract surgery.Br J Ophthalmol. 1990;74:19.

    Article  CAS  Google Scholar 

  5. Mahoney JM, Waterbury LD. (±) 5 benzoyl-1,2-dihydro-3H pyrrolo [1,2a] pyrrole-1-carboxylic acid (RS 37619]: a non irritating ophthalmic anti-inflammatory agent.Invest Ophthalmol Vis Sci. 1983;24:151–159.

    Google Scholar 

  6. Flach AJ, Kraff MC, Sanders DR, Tanenbaum L. The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on post surgical blood aqueous barrier.Arch Ophthalmol. 1998;106:480–483.

    Google Scholar 

  7. Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation, after cataract surgery: a randomized vehicle—controlled clinical trial.Am J Ophthalmol. 1999;127:253–259.

    Article  CAS  Google Scholar 

  8. Solomen KD, Cheetham JK, Degryse R, Brint SF, Rosenthal A. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery.Ophthalmology. 2001;108:331–337.

    Article  Google Scholar 

  9. Fraser-Smith EB, Mathews TR. Effect of ketorolac onCandida albicans ocular infection in rabbit.Arch Ophthalmol. 1987; 105:264–267.

    CAS  Google Scholar 

  10. Fraser-Smith EB, Mathews TR. Effect of ketorolac onPseudomonas aeruginosa ocular infection in rabbits.J Ocul Pharmacol. 1988; 4:101–109.

    Article  CAS  Google Scholar 

  11. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudoaphakic cystoid macular edema.Am J Ophthalmol. 1987;103:479–486.

    CAS  Google Scholar 

  12. Price FW Jr, Price MO, Zeh W, Dobbins K. Pain reduction after laser in situ keratomisleusis with ketorolac tromethamine ophthalmic solution 0.5%: a randomized, double-masked, placebo controlled trial.J Refract Surg. 2002;18:140–144.

    Google Scholar 

  13. Malhotra M, Majumdar DK. Effect of preservative, antioxidant and viscolizing agents on in vitro transcorneal permeation of ketorolac tromethamine.Indian J Exp Biol. 2002;40:555–559.

    CAS  Google Scholar 

  14. Malhotra M, Majumdar DK. In vitro transcorneal permeation of ketorolac from oil based ocular drops and ophthalmic ointment.Indian J Exp Biol. 1997;35:1324–1330.

    CAS  Google Scholar 

  15. Ling TL, Combs DL. Ocular bioavailability and tissue distribution of [14C] ketorolac tromethamine in rabbits.J Pharm Sci. 1987; 76:289–294.

    Article  CAS  Google Scholar 

  16. Madhu C, Rix PJ, Shackleton MJ, Nguyen TG, Tang-Liu DDS. Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillations to normal and de-epithelized corneas of rabbits.J Pharm Sci. 1996;85:415–418.

    Article  CAS  Google Scholar 

  17. Pharmacopoeia of India. 2nd ed. Delhi, India: Government of India, Ministry of Health and Family Welfare; 1970:203.

  18. Fu RC, Lidgate DM. In vitro rabbit corneal permeability study of ketorolac tromethamine.Drug Dev Ind Pharm. 1986;12:2403–2430.

    Article  CAS  Google Scholar 

  19. Grass GM, Wood RW, Robinson JR. Effects of calcium chelating agents on corneal permeability.Invest Ophthalmol Vis Sci. 1985;26:110.

    CAS  Google Scholar 

  20. Kennah HE, Higney S, Laux PE, Dorko JD, Barrow CS.Fundam Appl Toxicol. 1989;12:258–268.

    Article  CAS  Google Scholar 

  21. Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability 1. Evaluation of fluorometholone.J Pharm Sci. 1975;64:931.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dipak K. Majumdar.

Additional information

Published: October 24, 2005

Rights and permissions

Reprints and permissions

About this article

Cite this article

Malhotra, M., Majumdar, D.K. In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: A technical note. AAPS PharmSciTech 6, 65 (2005). https://doi.org/10.1208/pt060365

Download citation

  • Received:

  • Accepted:

  • DOI: https://doi.org/10.1208/pt060365

Keywords

Navigation